Affirming the order of the Tribunal the Court held that  amount received on surrender of  granted the right to market and sale of patent product of the assessee under the brand name of Pfizer. Court held that  surrender of the rights results in impairment of profit making apparatus of the assessee and therefore, is a capital receipt. (AY. 2000-01)